Laxmi Dental drops FY27 margin target after record quarter
Management walked back its 18-20% EBITDA margin guidance, citing domestic competition and macro uncertainty. Revenue hit a record ₹74 cr in Q4.
— 3 earlier stories on Laxmi Dental Ltd. →What's new
- Laxmi Dental posted record Q4 revenue of ₹74 cr, aided by a recovery in international lab business after US tariffs fell from 50% to 10%.
- Management refused to reaffirm its prior 18-20% EBITDA margin guidance for FY27, citing macro uncertainties and intensifying domestic competition.
- The company launched iScope 360, an AI-connected remote dental platform designed to generate subscription-based revenue.
Why this matters
A company pulling margin targets within months of setting them signals either competitive pressure or internal forecasting trouble. For a stock priced on growth, the loss of a credible earnings target removes a key anchor for valuation.
What we're watching
- Whether management provides a revised margin range or leaves guidance open-ended.
- How domestic aligner market competition is priced into upcoming results.
- Adoption metrics for the new iScope 360 subscription platform.
The full read
Laxmi Dental posted its highest-ever quarterly revenue of ₹74 cr in Q4, helped by the international lab business after US import tariffs fell from 50% to 10%. But the earnings call transcript reveals the more consequential development: management walked back its prior guidance of 18-20% EBITDA margins for FY27. The refusal to reaffirm that target, citing domestic competition and macro uncertainty, is a direct reversal of the story investors were told. The company also launched iScope 360, an AI-connected remote platform pitched as a future subscription revenue stream. The record quarter is a strong headline. The guidance withdrawal is what recalibrates the medium-term earnings thesis. The open question is whether this is a conservative reset or the first sign of deeper structural pressure in the aligner market.
Questions answered
- Why did Laxmi Dental withdraw its FY27 margin guidance?
- Management cited macro-economic uncertainties and intensifying domestic competition as reasons for not reaffirming the 18-20% EBITDA margin target. The walk-back represents a material shift in forward-looking sentiment.
- What drove the record Q4 revenue?
- Revenue of ₹74 cr was boosted by the recovery in the international laboratory business after US import tariffs were reduced from 50% to 10%.
- What is iScope 360?
- It is a new AI-connected remote dental platform launched by the company. It aims to improve patient compliance and create a new subscription-based revenue stream through monitoring services.
- How significant is the tariff change for the business?
- The US tariff reduction from 50% to 10% directly aided the international lab business recovery that contributed to the record quarter. The filing does not quantify the revenue impact.
Story so far
All notes on LAXMIDENTL →- 30 May 2026 · 3:18 PM IST Laxmi Dental drops FY27 margin target after record quarter
- 8d ago Laxmi Dental retreats from FY27 guidance after missing annual targets
- 9d ago Laxmi Dental releases routine Q4 and FY26 results
- 9d ago Laxmi Dental revenue climbs 22% as one-time gratuity costs bite